{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:08:08Z","timestamp":1787065688940,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#1\\u20132023"],"award-info":[{"award-number":["FFC#1\\u20132023"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["10\/2021"],"award-info":[{"award-number":["10\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcf.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:23:23Z","timestamp":1716510203000},"page":"1167-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5528-9550","authenticated-orcid":false,"given":"Dinu Zinovie","family":"Ciobanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-4753","authenticated-orcid":false,"given":"Nara","family":"Liessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-1916","authenticated-orcid":false,"given":"Valeria","family":"Tomati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-1171","authenticated-orcid":false,"given":"Valeria","family":"Capurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2922-6834","authenticated-orcid":false,"given":"Sine Mandrup","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Bertorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-7418","authenticated-orcid":false,"given":"Nicoletta","family":"Loberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-5912","authenticated-orcid":false,"given":"Dorina","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aureli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-3953","authenticated-orcid":false,"given":"Lucilla","family":"Nobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Bandiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-8755","authenticated-orcid":false,"given":"Andrea","family":"Armirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.05.004_bib0001","series-title":"EPAR medicine overview","year":"2022"},{"key":"10.1016\/j.jcf.2024.05.004_bib0002","article-title":"P245 Kaftrio\u00ae Impact and Side-effect Survey (KISS)","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.05.004_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.jcf.2024.05.004_bib0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2024.05.004_bib0005","series-title":"Kaftrio information file","year":"2021"},{"issue":"2\u20133","key":"10.1016\/j.jcf.2024.05.004_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood-brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jcf.2024.05.004_bib0007","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.004_bib0008","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.05.004_bib0009","unstructured":"A study to investigate the safety of kaftrio\u00ae in 2 to 5 year olds with cf, https:\/\/www.cysticfibrosis.org.uk\/get-involved\/clinical-trials\/trialstracker\/tt002106. 2021."},{"key":"10.1016\/j.jcf.2024.05.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.04.012","article-title":"The combination elexacaftor\/tezacaftor\/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner","author":"Liessi","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.004_bib0011","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI124159","article-title":"DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans","volume":"129","author":"Karsai","year":"2019","journal-title":"J Clin Invest"},{"issue":"1\u20133","key":"10.1016\/j.jcf.2024.05.004_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-5793(04)00274-1","article-title":"Identification of the human sphingolipid C4-hydroxylase, hDES2, and its up-regulation during keratinocyte differentiation","volume":"563","author":"Mizutani","year":"2004","journal-title":"FEBS Lett"},{"issue":"36","key":"10.1016\/j.jcf.2024.05.004_bib0013","doi-asserted-by":"crossref","first-page":"22432","DOI":"10.1074\/jbc.272.36.22432","article-title":"Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide","volume":"272","author":"Michel","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.004_bib0014","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nchembio.1114","article-title":"Identification of DES1 as a vitamin A isomerase in Muller glial cells of the retina","volume":"9","author":"Kaylor","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"9","key":"10.1016\/j.jcf.2024.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1194\/jlr.P094433","article-title":"Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway","volume":"60","author":"Blackburn","year":"2019","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.jcf.2024.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1172\/JCI123959","article-title":"Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy","volume":"129","author":"Pant","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.05.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101236","article-title":"The pathophysiological role of dihydroceramide desaturase in the nervous system","volume":"91","author":"Tzou","year":"2023","journal-title":"Prog Lipid Res"},{"issue":"11","key":"10.1016\/j.jcf.2024.05.004_bib0018","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41431-019-0444-z","article-title":"DEGS1 variant causes neurological disorder","volume":"27","author":"Dolgin","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176487","volume":"12","author":"Poliakov","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2024.05.004_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chemphyslip.2015.07.025","article-title":"Inhibitors of dihydroceramide desaturase 1: therapeutic agents and pharmacological tools to decipher the role of dihydroceramides in cell biology","volume":"197","author":"Casasampere","year":"2016","journal-title":"Chem Phys Lipids"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.004_bib0021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1165\/rcmb.2007-0036OC","article-title":"Fenretinide corrects newly found ceramide deficiency in cystic fibrosis","volume":"38","author":"Guilbault","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.004_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.004_bib0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-020-04224-8","article-title":"A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors","volume":"87","author":"Thomas","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.004_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous quantification of ivacaftor, tezacaftor, and elexacaftor in cystic fibrosis patients' Plasma by a novel LC-MS\/MS method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.004_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.004_bib0026","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1194\/jlr.RA120000627","article-title":"Dynamics of sphingolipids and the serine palmitoyltransferase complex in rat oligodendrocytes during myelination","volume":"61","author":"Davis","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jcf.2024.05.004_bib0027","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3389\/fneur.2020.00903","article-title":"Exploiting sphingo- and glycerophospholipid impairment to select effective drugs and biomarkers for CMT1A","volume":"11","author":"Visigalli","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.004_bib0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1113\/jphysiol.2012.240820","article-title":"Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability","volume":"591","author":"Farrar","year":"2012","journal-title":"J. Physiol. (Lond.)"},{"issue":"11","key":"10.1016\/j.jcf.2024.05.004_bib0029","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41593-021-00917-2","article-title":"Periods of synchronized myelin changes shape brain function and plasticity","volume":"24","author":"de Faria","year":"2021","journal-title":"Nat Neurosci"},{"issue":"8","key":"10.1016\/j.jcf.2024.05.004_bib0030","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF00968708","article-title":"Myelination in the developing human brain: biochemical correlates","volume":"19","author":"Kinney","year":"1994","journal-title":"Neurochem Res"},{"issue":"5","key":"10.1016\/j.jcf.2024.05.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019849","article-title":"Oligodendrocytes as Regulators of Neuronal Networks during Early Postnatal Development","volume":"6","author":"Doretto","year":"2011","journal-title":"PLoS One"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:14:54Z","timestamp":1778620494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1569199324000675"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}